IMNM (Immunome) FFO


IMNM Immunome Inc IMNM
44 GF Score
Price $19.77
GF Value $2.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Immunome FFO?

FFO (Funds from operations) only applies to REITs.

IMNM
44GF Score
Immunome Inc IMNM
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunome (IMNM) Overvalued in 2026?

Based on GuruFocus' analysis, Immunome stock appears to be overvalued. The current stock price of $19.77 is trading 878.7% above its estimated GF Value™ of $2.02. GuruFocus considers Immunome to be Significantly Overvalued.

Key valuation signals for IMNM:

  • FFO:
  • GF Value™: $2.02 vs. price of $19.77 (878.7% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunome Business Description

Address 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score

Get the complete analysis for IMNM

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.77
Price
$2.02
GF Value